AUG 23, 2021: FDA Grants Full Approval to Pfizer (PFE) and BioNTech (BNTX) COVID-19 Vaccine; (PFE) Acquires Trillium Therapeutics (TRIL) for $2.26 Billion

Pfizer (PFE) and BioNTech (BNTX) topped headlines this morning when the FDA announced its full approval of the two companies’ mRNA-based COVID-19 vaccination. The vaccination, marketed under the name “COMIRNATY” is the first COVID-19 vaccination to receive full FDA approval in the United States, potentially marking a path forward for other vaccinations such as those created by Moderna ($MRNA) and Johnson&Johnson ($JNJ) According to the CDC, the United States has thus far administered over 200 million doses of the Pfizer vaccine.

Receipt of FDA approval is a sweeping success, not just for the two companies, but for the public at large, as FDA approval increases confidence in the safety and efficacy of the vaccine. This added conviction from the FDA could lead businesses and universities to implement vaccine mandates.

After market open, large-flow options activity for PFE and BNTX were mixed, with a bullish-leaning sentiment for both; BNTX demonstrates a number of puts sold and purchased.

Pfizer also made waves in the Unusual Whales Live News Flow with a story of acquisition. Trillium Therapeutics (TRIL) and Pfizer announced earlier this morning that they have signed a decisive agreement for Pfizer to acquire Trillium (who specializes in immuno-oncology, the use of one’s own immune system to combat cancer) in an equity deal valued up to $2.26 billion.

Pfizer will acquire all outstanding Trillium shares for $18.50 a share. Trillium shares soared on the news, rising a factor of nearly 190% at the time of writing this, to $17.64 per share.Following the news, Options Activity for TRIL shows heavy bullish flow, with numerous large orders of sold puts and purchased calls alike, both indicative of the bullish sentiment surrounding Trillium Therapeutic’s acquisition by PFE.

Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.